Karyopharm Q2 FY26 net loss widens to $67 million; revenue falls 11.85% to $33.4 million - KPTI News | RalliesKaryopharm Q2 FY26 net loss widens to $67 million; revenue falls 11.85% to $33.4 million
K
KPTI• Karyopharm reports wider Q2 loss and lower revenue
- Karyopharm posted Q2 revenue of USD 33.4 million, down 11.86% from a year earlier.
- Net loss widened to USD 67 million, or USD 2.32 per share, from USD 37.3 million a year earlier.
- U.S. XPOVIO net product revenue rose to USD 30.8 million from USD 29.7 million; royalty revenue climbed to USD 2.5 million from USD 1.6 million.
- License and other revenue fell to USD 2.6 million from USD 8.2 million, tied to lower Menarini development-related reimbursement.
- Maintained 2026 revenue guidance of USD 130 million-USD 150 million; August sNDA filing for selinexor with ruxolitinib remains on track.
ROLR
•
